Faculty Advisor

Heilman, Destin

Project Center

University of Massachusetts Medical Center


The Hepatitis C virus infects nearly 170 million people worldwide, and is the major cause of hepatitis and liver cancer. The current treatment is a therapy with pegylated interferon and ribavirin, which has severe side effects. Recent addition of HCV NS3/4A protease inhibitors to this therapy has improved HCV treatments, but the severe side effects and rapid emergence of drug resistance limit the effectiveness of this therapy. Therefore, new HCV therapies must be developed that are effective against a broader spectrum of resistant viral variants and HCV genotypes. This project followed the multi-step synthesis of a new variant of the MK-5172 inhibitor, evaluated the synthesis plan, and provided the UMass Medical School with a new inhibitor to test activity against NS3/4A protease variants.


Worcester Polytechnic Institute

Date Accepted

April 2013



Project Type

Major Qualifying Project



Advisor Department

Chemistry and Biochemistry

Your accessibility may vary due to other restrictions.